Copyright
©The Author(s) 2023.
World J Diabetes. Mar 15, 2023; 14(3): 234-254
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.234
Published online Mar 15, 2023. doi: 10.4239/wjd.v14.i3.234
Figure 3 Tongxinluo inhibited endothelial cell pyroptosis.
A: Immunofluorescence staining for assessment of reactive oxygen species (ROS) levels in ischemic hindlimbs (400×, bar = 50 μm); B: Quantification of the mean fluorescence intensity of ROS; C-G: Western blot analysis of the expression of the pyroptosis-associated proteins NLRP3, GSDMD, Caspase-1 and Cleaved caspase-1 in the ischemic adductor; H and I: The pyroptosis-associated inflammatory cytokines IL-18 and IL-1β were analyzed by ELISA. The values are shown as the means ± SDs. aP < 0.05 compared with the normal group, bP < 0.05 compared with the model group, cP < 0.05 compared with the Tongxinluo-L group, n = 3-4. ROS: Reactive oxygen species; TXL: Tongxinluo.
- Citation: Gu JJ, Hou YL, Yan YH, Li J, Wei YR, Ma K, Wang XQ, Zhang JH, Wang DD, Li CR, Li DQ, Sun LL, Gao HL. Tongxinluo promotes endothelium-dependent arteriogenesis to attenuate diabetic peripheral arterial disease. World J Diabetes 2023; 14(3): 234-254
- URL: https://www.wjgnet.com/1948-9358/full/v14/i3/234.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i3.234